Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
Gil Yosipovitch(University of Miami), A. Gadkari(Regeneron (United States)), Nicole Williams(RTI Health Solutions), Allen Radin(Regeneron (United States)), Adeline Abbé(Sanofi (France)), M. Clark(RTI Health Solutions), Marius Ardeleanu(Regeneron (United States)), Vera Mastey(Regeneron (United States)), Stefan Plaum(Sanofi (United States)), Bolanle Akinlade(Regeneron (United States)), Z. Chen(Regeneron (United States)), Neil M.H. Graham(UK Dementia Research Institute), Heribert Staudinger(Sanofi (United States)), Gianluca Pirozzi(Sanofi (United States)), Lauren Nelson(RTI Health Solutions), Laurent Eckert(Sanofi (France)), Matthew Reaney(Sanofi (United Kingdom))
Cited by 384
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516